Junli Li

Junli Li

Auto-generated profile, based on publicly available information

Junli Li

Laboratory of Cardiac Structure and Function, Institute of Cardiovascular Diseases, West China Hospital, Sichuan University, Chengdu, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2020 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
JZJunteng Zhou
Junteng Zhou
GTGeer Tian
Geer Tian
YQYue Quan
Yue Quan
JLJunli Li
Junli Li
XWXiaojiao Wang
Xiaojiao Wang
XLXiaojing Liu
Xiaojing Liu
P2X7 purinergic receptor (P2X7R) has been implicated in several cardiovascular diseases. However, whether it regulates cardiac fibrosis remains elusive. Herein, its involvement in the development of cardiac fibrosis was examined using a transverse aortic constriction (TAC) mice model and cardiac fibroblasts (CFs) hyperstimulated by TGF-β1 for 48 hours. Results showed that TAC and TGF-β1 treatment increased the expression of P2X7R. Silencing of P2X7R expression with siP2X7R ameliorated TGF-β1 effects on fibroblasts activation. Similarly, P2X7R inhibition by Brilliant Blue G (BBG) reduced mRNA and protein levels of profibrosis markers, while the P2X7R agonist BzATP accelerated the TGF-β1-induced CFs activation. Moreover, it was found that TGF-β1-induced CFs activation was mediated by the NLRP3/IL-1β inflammasome pathway. BBG or siP2X7R treatment suppressed NLRP3/IL-1β pathway signaling. In vivo, BBG significantly alleviated TAC-induced cardiac fibrosis, cardiac dysfunction, and NLRP3/IL-1β activation. Collectively, our findings imply that suppressing P2X7R may limit cardiac fibrosis and abnormal activation of CFs.

1 April 2024 in Bioactive Materials
Verified
Journal Article
Open access
QLQiang Luo
Qiang Luo
LDLiqun Dai
Liqun Dai
JLJunli Li
Junli Li
HCHeyanni Chen
Heyanni Chen
YHYing Hao
Ying Hao
MCMao Chen
Mao Chen
Atherosclerosis is a significant contributor to global cardiovascular disease. Reducing the formation of atherosclerotic plaque effectively can lead to a decrease in cardiovascular diseases. Therefore, controlling macrophage function is crucial. This study presents the creation of a bifunctional nanoparticle that is specific to macrophages to achieve intracellular and extracellular synergistic therapy for restoring macrophage functions. The nanoparticle is conjugated with anti-CD47 antibody to modulate extracellular CD47-SIRPα phagocytic signaling axis on the outer surface of macrophages and encapsulates the NLRP3 inhibitor (CY-09) to regulate intracellular inflammation response of macrophages. The results showed that the nanoparticles accumulate in the atherosclerotic plaque, alter macrophage phagocytosis, inhibit NLRP3 inflammasome activation, and decrease the plaque burden in Apoe-/- mice whilst ensuring safety. Examination of single-cell RNA sequencing indicates that this multifunctional nanoparticle decreases the expression of genes linked to inflammation and manages inflammatory pathways in the plaque lesion. This study proposes a synergistic therapeutic approach that utilizes a bifunctional nanoparticle, conjugated with anti-CD47, to regulate the microenvironment of plaques.

1 January 2025 in Cardiovascular Therapeutics
Verified
Journal Article
Open access
QLQing Li
Qing Li
CSChengxiang Song
Chengxiang Song
ZWZisong Wei
Zisong Wei
JLJunli Li
Junli Li
HZHao Zhou
Hao Zhou
CMChen Mao
Chen Mao
Objective: Calcific aortic valve disease (CAVD) is a progressive cardiovascular condition driven by the osteogenic differentiation of valve interstitial cells (VICs), with no effective drug therapies currently available. Hence, our objective is to investigate the impact of thrombospondin‐1 (TSP‐1) silencing on CAVD progression. Methods: In vitro experiments were employed using human primary VICs with TSP‐1 knockdown, cultured in osteogenic induction medium, and followed by analyses including western blot, alkaline phosphatase staining, alizarin red staining, immunofluorescence, and flow cytometry. In vivo experiments used two murine models of CAVD to determine the role of TSP‐1 silencing on aortic valve calcification. Results: We observed that silencing of TSP‐1 reduced the osteogenic differentiation of VICs. Subsequent experiments demonstrated that TSP‐1 knockdown suppressed nuclear factor‐ κ B (NF‐ κ B)–mediated inflammation during osteoblastic differentiation of VICs. Consistent findings were also observed in two murine models of CAVD. Conclusions: The present study has shown that TSP‐1 silencing could mitigate the development of CAVD by inhibiting NF‐ κ B‐mediated inflammation. We propose that targeting TSP‐1‐mediated NF‐ κ B pathway could provide a potential therapeutic method for treating CAVD.